TNFRSF9 and neoplasm: For example, interaction of anti-4-1BB mAb with activatory FcγR leads to Treg deletion whilst cross-linking by FcγRIIB is required for efficient co-stimulation of CD8+ effectors, with both mechanisms giving anti-tumor activity in pre-clinical models [121].